Bausch + Lomb Announces Statistically Significant Topline Results from Second Phase 3 Trial of NOV03

Bausch + Lomb and Novaliq announced statistically significant topline data from the second Phase 3 (MOJAVE) trial evaluating the investigational...

Read More